Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clinical Study of Antibody-Drug Conjugate MYTX-011 in Subjects With Non-Small Cell Lung Cancer
2023-504630-22-00Phase 2Completed
- Sponsor
- Mythic Therapeutics
- Start
- Apr 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 7
01
Overview
Phase 2 trial of mytx-011 in non-small cell lung cancer (NSCLC), sponsored by Mythic Therapeutics. Started Apr 2024; status: completed.
02
Drugs
mytx-011
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2023-504630-22-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504630-22-00.